3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione | 702676-10-6

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione
• 英文别名: 3-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]pyrimidin-2-yl]amino]phenyl]imidazolidine-2,4-dione
• CAS: 702676-10-6
• 化学式: C₁₈H₁₇BrN₈O₂
• 分子量: 457.289
• InChiKey: RAGQZOQPPRERMD-UHFFFAOYSA-N

物化性质

• 密度：
  1.694±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• [EN] CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS<br/>[FR] PYRIMIDINES INHIBITRICES DE CHK-, PDK- ET DE AKT, PRODUCTION ET UTILISATION DE CES COMPOSES COMME AGENTS PHARMACEUTIQUES
  申请人：SCHERING AG

  公开号：WO2004048343A1

  公开（公告）日：2004-06-10

  This invention relates to pyrimidine derivatives of general formula (I) as inhibitors of kinases, their production as well as their use as medications for treating various diseases.

  这项发明涉及通式（I）的嘧啶衍生物作为激酶抑制剂，它们的生产以及它们作为治疗各种疾病的药物的用途。
• Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
  申请人：——

  公开号：US20040186118A1

  公开（公告）日：2004-09-23

  This invention relates to pyrimidine derivatives of general formula (I) as inhibitors of kinases, their production as well as their use as medications for treating various diseases

  本发明涉及一种通式（I）的嘧啶衍生物，作为激酶抑制剂，其制备以及它们作为治疗各种疾病的药物的用途。
• CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS
  申请人：Schering Aktiengesellschaft

  公开号：EP1565446A1

  公开（公告）日：2005-08-24
• USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20180071244A1

  公开（公告）日：2018-03-15

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.
• US7504410B2
  申请人：——

  公开号：US7504410B2

  公开（公告）日：2009-03-17